GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Legend Biotech
Legend Biotech is a biotech company that, in partnership with J&J, developed a successful CAR-T therapy for the treatment of blood cancer. Its stock price reflects the commercial success of this breakthrough drug and the potential of its cell platform for the development of new drugs.
Share prices of companies in the market segment - Oncology cell gene therapy
Legend Biotech is a pioneer in the CAR-T therapy segment, having developed Carvykti in partnership with J&J. We classify it in the Oncology Cell/Gene Therapy sector. The chart below shows the dynamics of this revolutionary yet complex segment.
Broad Market Index - GURU.Markets
Legend Biotech is a biotech company that, in partnership with J&J, developed a successful CAR-T therapy for the treatment of multiple myeloma. Its breakthrough product earned it a spot in the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
LEGN - Daily change in the company's share price Legend Biotech
The volatility of Legend Biotech (LEGN), a biotech company focused on cancer cell therapy, is reflected in Change_Co, which is hypersensitive to clinical trial results and partnerships. Change_Co is a measure of extreme volatility in the advanced medicine sector. This metric is critical for formulaic analysis of high-risk and high-potential assets.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Legend Biotech Corporation is a biotech company pioneering cell therapy. This chart highlights the sector's extreme volatility. Comparing it to LEGN, whose success hinges on a single drug for the treatment of multiple myeloma, helps to understand its high concentration risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Legend Biotech is a biopharmaceutical company pioneering the development of CAR-T therapy for the treatment of multiple myeloma. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below reflects the average fluctuations in this industry, serving as a benchmark for valuing Legend shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Legend Biotech
Legend Biotech, in partnership with J&J, achieved a breakthrough in the treatment of multiple myeloma with its drug Carvykti. Its year-over-year stock price performance, shown in the chart, directly reflects the drug's phenomenal success and its growing use.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Legend Biotech Corporation is a biotech company pioneering cell therapy for cancer treatment. Its partnership with Johnson & Johnson to commercialize CAR-T therapy was a breakthrough. This chart shows how the market views the commercial potential of its innovative platform compared to the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Legend Biotech is a story of breakthroughs in cancer treatment using cell therapy. Its stock price is completely detached from economic cycles and is driven by clinical successes, partnerships, and regulatory decisions. The company's price chart reflects investor hopes for a medical revolution, not the state of the global economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Legend Biotech
Legend Biotech, a pioneer in cancer cell therapy, developed Carvykti in collaboration with J&J. The sharp monthly fluctuations on the chart reflect sales data for this innovative drug and news about its expanded use in the treatment of multiple myeloma.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
This chart reflects the dynamics of the biotech sector, particularly in the cell therapy segment, where Legend is a leader. Its movements demonstrate how breakthrough FDA approvals and commercial successes like Carvykti can create a powerful trend for the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed and commercialized the CAR-T therapy Carvykti for the treatment of multiple myeloma. The chart below shows general market trends. Does Legend live in a world where momentum is determined by the success of a single breakthrough drug?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Legend Biotech
Legend Biotech, a cancer cell therapy company, is showing the typical dynamics of an innovative biotech company. Weekly share price fluctuations reflect clinical trial data, partnerships with major pharma, and news of the commercialization of its therapies.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Legend Biotech operates in the revolutionary cell therapy sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment, while failure can dampen investor interest. The chart will reveal whether the market perceives LEGN as a leader in this movement or simply part of it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Legend Biotech often ignores broader market trends. Its fate depends not on GDP or inflation, but on clinical trial results and FDA decisions. The chart below clearly demonstrates how LEGN shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
LEGN - Market capitalization of the company Legend Biotech
Legend Biotech's stock chart reflects the cutting edge of the fight against cancer. The company is a pioneer in CAR-T cell therapy. Its market cap growth reflects investors' direct bets on the success of its innovative treatment for multiple myeloma and other oncological diseases. It's a story of hope embodied in biotechnology.
LEGN - Share of the company's market capitalization Legend Biotech within the market segment - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company pioneering CAR-T cell therapy for cancer treatment. Its share of the market cap of its innovation segment reflects the breakthrough nature of its technology. The chart below shows how the market views the commercial potential of its drug, Carvykti, and its partnership with Johnson & Johnson.
Market capitalization of the market segment - Oncology cell gene therapy
Legend Biotech is a biotech company developing cutting-edge cell therapy methods for cancer treatment. The chart below shows the market capitalization of the gene and cell therapy oncotherapy sector. This represents one of the most breakthrough and promising areas in modern medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Legend Biotech is a biotech company pioneering CAR-T cell therapy for multiple myeloma. Its high market cap reflects the revolutionary potential of its technology in the fight against cancer. In the pharmaceutical industry as a whole, its value represents the weight of personalized medicine, which uses a patient's own cells to destroy tumors.
Book value capitalization of the company, segment and market as a whole
LEGN - Book value capitalization of the company Legend Biotech
Legend Biotech's book value represents the capital invested in cancer cell therapy. It consists of advanced manufacturing facilities for CAR-T therapy, R&D laboratories, and significant cash reserves for global clinical trials. The chart below shows how the company built its complex biotech foundation to fight cancer.
LEGN - Share of the company's book capitalization Legend Biotech within the market segment - Oncology cell gene therapy
Legend Biotech develops cell therapies in its cutting-edge research and production centers. These sterile labs and bioreactors are its main tangible assets. The S_BCap_Seg chart shows the company's control over this unique infrastructure in the gene therapy sector.
Market segment balance sheet capitalization - Oncology cell gene therapy
The chart shows the overall book value of the biotech sector. Against this backdrop, Legend Biotech, as a pioneer in cell therapy, is highly capital-intensive. The development and production of CAR-T therapy requires the ownership of highly sophisticated and ultra-clean production facilities—"living drug factories."
Book value of all companies included in the broad market index - GURU.Markets
Legend Biotech is a pioneer in cancer cell therapy. Its assets are not giant factories, but state-of-the-art laboratories and production facilities where patients' cells are transformed into medicine. Among the pharmaceutical industry as a whole, Legend represents its most advanced and personalized "workshop," a physical embodiment of the future of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Legend Biotech
Legend Biotech's balance sheet is the value of its cell therapy manufacturing facilities. Its market capitalization represents a huge bet on the success of its drug, Carvykti. The MvsBCap_Co chart shows how much the market values one revolutionary cancer drug over all the company's tangible assets combined.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Legend Biotech is a biotech company that has achieved success in cancer cell therapy. The chart shows the enormous premium the market places on its approved drug, Carvykti, and its scientific potential. This is a prime example of how a single successful product can determine the value of an entire company.
Market to book capitalization ratio for the market as a whole
Legend Biotech is a biotech company specializing in cell therapy for cancer, specifically multiple myeloma. Its value is driven by its breakthrough CAR-T technology and partnership with Janssen. This chart illustrates why investors are willing to pay a hefty premium for the potential of revolutionary cancer treatments.
Debts of the company, segment and market as a whole
LEGN - Company debts Legend Biotech
Legend Biotech, a biopharmaceutical company specializing in cancer cell therapy, uses debt to fund cutting-edge research. This chart shows how the company is raising significant funds to conduct clinical trials and bring its innovative treatments to market. In this disruptive field of medicine, debt is a bridge to the future.
Market segment debts - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company that has successfully developed CAR-T cell therapy for multiple myeloma. Developing and commercializing such breakthrough cancer treatments requires massive investments. This chart shows how the company funds its cutting-edge, yet very expensive, research and manufacturing processes.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Legend Biotech
Legend Biotech is a biotech company that, in partnership with J&J, developed a breakthrough cell therapy for the treatment of multiple myeloma. This chart shows the company's financial position during the rapid sales growth phase. Capital is being used to expand production capacity and fund further research into applying this technology to other cancer types.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Legend Biotech is a biotech company that achieved success with Carvykti, a cell therapy for multiple myeloma. This chart shows debt trends in their segment. It allows one to assess how the company is financing production scaling and further research with a blockbuster in hand, and how its financial strategy compares to its partners and competitors.
Debt to book value of all companies in the market
Legend Biotech, a pioneer in cell therapy. The chart reflects the overall market leverage. It helps understand how funding for such breakthrough medical technologies depends on overall investor risk appetite. Does capital continue to flow into the industry to support production and new research, even when the market as a whole is risk-averse?
P/E of the company, segment and market as a whole
P/E - Legend Biotech
This chart shows the valuation of Legend Biotech, a biopharmaceutical company that developed a successful CAR-T therapy for multiple myeloma in collaboration with J&J. The very high price-to-earnings ratio indicates high sales expectations for this drug. The dynamics of this ratio depend entirely on a successful commercial launch and the expansion of the therapy's use.
P/E of the market segment - Oncology cell gene therapy
This is the average P/E ratio for biotech companies involved in cell therapy. For Legend Biotech, with its already approved and successful drug, this is an important benchmark. Its P/E is likely to be above average, reflecting not just potential but already realized commercial success, which distinguishes it from many companies in the development stage.
P/E of the market as a whole
Legend Biotech is a biopharmaceutical company that has successfully developed CAR-T therapy for multiple myeloma. Its future depends on the commercial success of this drug and the development of other cell therapies. This chart of overall market sentiment demonstrates how high investor expectations are for this revolutionary cancer treatment technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Legend Biotech
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed a successful CAR-T therapy for the treatment of multiple myeloma. The company's future depends on the growth of this drug's sales and the success of other developments in its pipeline. This graph reflects the market's high expectations regarding the potential of cell therapy in oncology and the commercial success of its first product.
%20P%2FE%20Legend%20Biotech&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Legend-Biotech&v=1772559038634 "Chart of the company's future (projected) P/E Legend Biotech")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed and commercialized Carvykti, a successful CAR-T therapy for multiple myeloma. This represents a breakthrough in cancer treatment. The chart reflects expectations for the biotech sector, helping to assess how highly the market values this commercial success and the potential of Legend's platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772559038770 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Legend Biotech is a biotech company pioneering CAR-T cell therapy for cancer. Their success depends on scientific breakthroughs and the commercialization of complex treatments. This graph of overall expectations reflects investor sentiment toward innovation. Market optimism is driving capital flows into biotech, allowing companies like Legend to fund expensive research and production.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772559038803 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Legend Biotech
Legend Biotech is a biopharmaceutical company focused on cell therapy for cancer treatment. This chart highlights the potential for breakthrough oncology treatment. The company partnered with Johnson & Johnson to commercialize Carvykti. Revenue growth will depend on the success of this drug and its expanded use across various cancer types.
Profit of companies in the market segment - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company developing cell therapy (CAR-T) for cancer treatment in partnership with Johnson & Johnson. Profitability depends on the success of their joint drug. This chart reflects the potential of biotech, where a single breakthrough product can radically transform a company's financial position and set a new standard of care.
Overall market profit
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed a successful CAR-T therapy for the treatment of multiple myeloma. The company's success depends on the commercialization of its drug and the expansion of its indications. This is a shining example of how a medical breakthrough can create a multibillion-dollar business unaffected by market cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Legend Biotech
Legend Biotech is a biopharmaceutical company that, in partnership with Johnson & Johnson, developed a successful CAR-T therapy for the treatment of multiple myeloma. Its revenue forecast depends on the commercial success of this drug and the development of other cell therapies. This chart reflects analyst expectations for the growth of the gene and cell therapy market in oncology.
%20profit%20of%20the%20company%20Legend%20Biotech&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Legend-Biotech&v=1772559038881 "Graph of future (projected) profit of the company Legend Biotech")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed and commercialized Carvykti, a CAR-T therapy for multiple myeloma. This represents a breakthrough in the treatment of blood cancer. This chart shows profitability forecasts for the biotech sector. It reflects the commercial potential of cell therapy and expectations for one of the most innovative drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772559038906 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Legend Biotech is a biotech company at the forefront of the fight against cancer using CAR-T cell therapy. Its value is determined by the potential of its scientific developments. This graph, reflecting the overall state of the economy, influences the investment climate. During periods of optimism, the market is more willing to fund breakthrough but risky biotech companies like Legend.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772559038982 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Legend Biotech
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed a breakthrough CAR-T therapy for the treatment of multiple myeloma. Its revenue is a percentage of sales of this innovative, but very expensive, drug. The chart shows how highly the market values its technology and the potential for cell therapy in cancer treatment.
P/S market segment - Oncology cell gene therapy
Legend Biotech Corporation is a global clinical-stage biopharmaceutical company focused on developing and commercializing novel cell therapies for the treatment of cancer and other diseases. This chart reflects investor expectations for companies in the sector, providing insight into how the market values Legend Biotech's cutting-edge technologies.
P/S of the market as a whole
Legend Biotech is a biopharmaceutical company developing cell therapies for cancer. Its lead product, Carvykti, is showing impressive results in the treatment of myeloma. This chart, showing average valuations, clearly demonstrates the significant premium investors place on the company's revenue, which is at the forefront of the oncology revolution.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Legend Biotech
Legend Biotech is a biotech company specializing in developing cell therapies for cancer. This chart reflects investors' high expectations for the future success of its CAR-T therapy. The valuation is based on sales projections for the approved drug and the potential of its research platform.
%20P%2FS%20Legend%20Biotech&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Legend-Biotech&v=1772559039205 "The graph of the company's future (projected) P/S Legend Biotech")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed a breakthrough cell therapy for the treatment of multiple myeloma. This chart compares the company's estimated future sales with its industry. It reflects the high expectations of investors for the commercial success of this drug and the potential of the entire CAR-T therapy platform.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772559039257 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
This chart reflects investor confidence in revolutionary cancer treatments. Legend Biotech, together with its partners, has developed CAR-T cell therapy, which has demonstrated remarkable results. The success of their drug and growing sales inspire enormous optimism in the biotech sector and demonstrate the potential for personalized medicine to drive future growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772559039315 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Legend Biotech
Legend Biotech is a biotech company that, together with a partner, developed and commercialized the CAR-T therapy Carvykti for the treatment of multiple myeloma. Its revenue primarily comes from sales of this innovative and expensive drug. This chart illustrates the commercial success of one of the most advanced cancer treatments.
Sales of companies in the market segment - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company that has achieved a breakthrough in the treatment of multiple myeloma with its CAR-T cell therapy, Carvykti, developed in partnership with Johnson & Johnson. This chart shows total revenue in the cell and gene therapy sector. It demonstrates the rapid growth of this cutting-edge oncology field, where Legend Biotech is a key innovator.
Overall market sales
Legend Biotech is a biopharmaceutical company focused on cell therapy for cancer, best known for its CAR-T drug for multiple myeloma. Its success depends on the commercialization and adoption of its innovative therapy. This graph, based on the overall economic situation, has less of an impact on demand, which is primarily determined by patient needs and healthcare system capacity.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Legend Biotech
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed a cutting-edge cell therapy (CAR-T) for the treatment of multiple myeloma. Its success depends on the commercialization of this drug. The chart shows analysts' revenue forecasts, reflecting their expectations for sales growth of this innovative and expensive treatment.
%20sales%20of%20the%20company%20Legend%20Biotech&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Legend-Biotech&v=1772559039416 "Schedule of future (projected) sales of the company Legend Biotech")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company developing innovative cell therapies for cancer treatment, particularly CAR-T therapy. Its success depends on clinical trial results and regulatory approval. This chart reflects projected sales for the entire cell and gene therapy sector, highlighting the expected growth of this cutting-edge field in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772559039469 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Legend Biotech is a biopharmaceutical company developing cell therapy (CAR-T) for cancer treatment. Its future depends on the success of clinical trials and the market acceptance of its innovative treatments. This overall economic activity schedule impacts the availability of funding for the biotech sector and the willingness of healthcare systems to pay for expensive treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772559039479 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Legend Biotech
Legend Biotech is a biotech company that has achieved success with CAR-T therapy for multiple myeloma. This chart shows the financial impact of this scientific breakthrough. It reflects how successfully the company converts revenue from its innovative drug into net profit, a key goal for the entire biotech industry.
Market segment marginality - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company that achieved success with its Carvykti cell therapy for multiple myeloma, developed in partnership with Johnson & Johnson. This chart depicts its operational structure during the rapid commercialization phase of its breakthrough product. It shows how the company manages manufacturing and sales compared to other biotechs.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Legend Biotech
Legend Biotech is a biotech company that has achieved success in CAR-T cell therapy for cancer. This chart illustrates its rapid transformation from a research firm to a commercial one. The growth in staff reflects the expansion of its manufacturing capacity and the creation of a commercial team to bring its innovative drug to market.
Share of the company's employees Legend Biotech within the market segment - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company developing cell therapies for cancer. This chart shows the concentration of leading scientists in the field of genetic and cellular engineering. This share reflects its role as a leader in the development of a revolutionary cancer treatment method—CAR-T therapy.
Number of employees in the market segment - Oncology cell gene therapy
Legend Biotech is a biotech company focused on cell therapy for cancer, best known for its CAR-T drug for multiple myeloma. This chart shows the overall employment in the cell and gene therapy sector. Its exponential growth reflects the revolution in cancer treatment and the massive investment being attracted to this cutting-edge field.
Number of employees in the market as a whole
Legend Biotech is a biotech company that, in partnership with Johnson & Johnson, developed a breakthrough CAR-T therapy for the treatment of multiple myeloma. The growth in personnel on this chart reflects the transition from clinical trials to global commercial launch. The company is building manufacturing facilities and hiring specialists to bring its drug to market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Legend Biotech (LEGN)
Legend Biotech is a biopharmaceutical company developing cell therapy for cancer. This chart shows that the market is placing an astronomical valuation on its breakthrough technology. Its market cap is based on expectations for its drug. The high cost per employee reflects its intellectual property and potential to save lives.
%20of%20the%20company%20Legend%20Biotech%20(LEGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Legend-Biotech-LEGN&v=1772559040192 "Chart of market capitalization per employee (in thousands of dollars) of the company Legend Biotech (LEGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Legend Biotech is a biotech company that developed (in collaboration with J&J) a successful CAR-T therapy (Carvykti) for the treatment of multiple myeloma. It's an R&D-intensive, IP-based business. Its value lies in its patents. This metric, compared to the industry average, reflects the significant premium the market pays for their breakthrough technology.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772559040230 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Legend Biotech is a biopharmaceutical company specializing in cell therapy for cancer treatment. Its valuation is based on its breakthrough CAR-T technology. Its extremely high market capitalization per employee reflects investors' high expectations for the potential of this innovative therapy, which could transform approaches to cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772559040254 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Legend Biotech (LEGN)
Legend Biotech is a biotech company developing cell therapy (CAR-T) for cancer treatment, in partnership with J&J. This is at the cutting edge of medicine, requiring enormous research and production costs. This chart shows how much net profit (or loss) each scientist working on these "living drugs" generates.
%20Chart%20Legend%20Biotech%20(LEGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Legend-Biotech-LEGN&v=1772559040287 "Company Profit Per Employee (in thousands of dollars) Chart Legend Biotech (LEGN)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Legend Biotech (LEGN) is a biotech company (a JNJ partner) that developed CAR-T therapy (Carvykti) for multiple myeloma. This chart shows the benchmark for oncology cell gene therapy. This benchmark (likely negative) reflects the R&D budget being burned through the development of personalized cancer therapies.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772559040312 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Legend Biotech (LEGN) is a biopharmaceutical company developing CAR-T cell therapy for cancer. Their partnership with J&J on Carvykti is a breakthrough in myeloma treatment. This chart, showing average profit per employee, is important for biotech. It allows us to assess how much the gene therapy sector, where scientists are crucial, outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772559040324 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Legend Biotech (LEGN)
For Legend Biotech, a company developing cell therapy for cancer, this chart reflects the commercial success of its breakthrough drug, Carvykti. The astronomical revenue per employee is a result of the very high cost and effectiveness of this innovative myeloma treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Legend-Biotech-LEGN&v=1772559040356 "Sales chart per company employee Legend Biotech (LEGN)")
Sales per employee in the market segment - Oncology cell gene therapy
Legend Biotech is a biopharmaceutical company focused on cancer cell therapy, known for its drug Carvykti. This metric reflects average revenue per employee by segment. It allows us to assess how productive Legend's team is in promoting and manufacturing this highly complex therapy compared to other companies in the CAR-T field.
Sales per employee for the market as a whole
Legend Biotech (LEGN) is a biopharmaceutical company developing cell therapy (CAR-T) for cancer treatment, in partnership with J&J. For a biotech company in the commercialization stage (with Carvykti), this metric reflects a manufacturing and commercial breakthrough. The growth in revenue per employee indicates successful patient treatment and the scaling of the highly complex manufacturing process for this therapy.
Short shares by company, segment and market as a whole
Shares shorted by company Legend Biotech (LEGN)
Legend Biotech is a biopharmaceutical company that, in partnership with J&J, developed Carvykti, a breakthrough CAR-T cell therapy for the treatment of multiple myeloma. The company's success hinges on a single product. This chart reflects investor bets on the enormous manufacturing and logistical challenges of scaling CAR-T therapy, as well as the risks of high concentration.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Legend-Biotech-LEGN&v=1772559040510 "Short Shares Chart for the Company Legend Biotech (LEGN)")
Shares shorted by market segment - Oncology cell gene therapy
Legend Biotech (LEGN) is a cell therapy biotech best known for its CAR-T therapy (Carvykti) for the treatment of multiple myeloma. This chart shows the cumulative short position in the cell gene therapy sector. It reflects investor concerns about the high cost and complexity of manufacturing such treatments.
Shares shorted by the overall market
Legend Biotech is a biotech company focused on cell therapy (Carvykti). The rise in Short_All suggests that investors are fearful and risk-averse. This pessimism could deprive companies like LEGN of needed capital, as the market's focus shifts from long-term medical breakthroughs to short-term asset preservation.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Legend Biotech (LEGN)
Legend Biotech is a biotech disruptor that co-created (with J&J) Carvykti, a breakthrough CAR-T therapy. **This chart** measures the response to binary events. News that the FDA is expanding Carvykti's use (approval for earlier stages of cancer) can trigger explosive growth and euphoria, pushing **This chart** above 70.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Legend-Biotech-LEGN&v=1772559040602 "RSI 14 indicator chart for the company's stock Legend Biotech (LEGN)")
RSI 14 Market Segment - Oncology cell gene therapy
Legend Biotech Corporation is a biopharmaceutical company at the forefront of cell therapy. Its lead product, Carvykti (in partnership with J&J), is a breakthrough treatment for multiple myeloma (a blood cancer). This chart shows the overall sentiment in the gene and cell therapy oncotherapy sector. It helps assess whether LEGN's momentum reflects its clinical success or the general hype surrounding this technology.
RSI 14 for the overall market
Legend Biotech (LEGN) is a biotech company specializing in CAR-T cell therapy for cancer. Their drug, Carvykti, is showing outstanding results. This "risk appetite" indicator is important for biotech companies. During periods of euphoria (high values), investors value breakthrough technologies. During periods of panic (low values), the focus shifts to profitability, which LEGN currently lacks.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LEGN (Legend Biotech)
Legend Biotech (LEGN) is a biopharmaceutical company focused on cancer cell therapy. Their key success is their partnership with J&J on Carvykti, a CAR-T therapy for myeloma. This chart shows the average analyst forecast, reflecting their high expectations for Carvykti sales and success in expanding production capacity for this complex therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LEGN-Legend-Biotech&v=1772559040734 "A chart showing analyst consensus forecasts for the expected stock price. LEGN (Legend Biotech)")
The difference between the consensus estimate and the actual stock price LEGN (Legend Biotech)
Legend Biotech is a biopharmaceutical company (in partnership with J&J) that developed Carvykti, a breakthrough CAR-T therapy for multiple myeloma. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the commercial success and broad application of Carvykti.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LEGN-Legend-Biotech&v=1772559040789 "A chart showing the difference between the consensus forecast and the actual stock price. LEGN (Legend Biotech)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Legend Biotech is a pioneer in cell therapy. Together with J&J, the company developed Carvykti, a breakthrough CAR-T drug for the treatment of multiple myeloma (blood cancer). This chart shows analysts' overall expectations for the cell therapy sector, reflecting whether experts believe this revolutionary, but expensive, technology will be commercially successful.
Analysts' consensus forecast for the overall market share price
Legend Biotech (LEGN) is a biotech company working at the forefront of cell therapy (CAR-T) for cancer treatment. It's a risky but disruptive business. This chart of overall market sentiment is important. Optimism = the market is willing to fund expensive clinical trials and believe in the future of the therapy. Pessimism = risk aversion from unprofitable biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Legend Biotech
Legend Biotech is a biotech company (in partnership with J&J) behind a breakthrough CAR-T therapy (Carvykti) for the treatment of multiple myeloma. It's a living drug created from a patient's cells. This chart is an assessment of their breakthrough. It reflects the pace of Carvykti's commercialization, their ability to scale up complex manufacturing, and the expected applications of this therapy.
AKIMA Market Segment Index - Oncology cell gene therapy
Legend Biotech (LEGN) is a cell therapy pioneer; a biotech company (in partnership with JNJ) that developed a breakthrough CAR-T therapy (Carvykti) for the treatment of multiple myeloma (blood cancer). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Legend's breakthrough CAR-T platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Legend Biotech is a biotech company that, together with J&J, developed one of the most successful CAR-T therapies (Carvykti) for the treatment of blood cancer. It's a breakthrough scientific story. This chart, reflecting the market average, is the backdrop. It helps assess how this innovative biotech company stacks up against the backdrop of overall economic trends.
